Document |
Document Title |
WO/2023/215494A1 |
Described herein are compounds that are ULK1/2 inhibitors and their use in the treatment of disorders such as cancers.
|
WO/2023/196875A1 |
The present disclosure relates generally to compounds, of Formula I: Also disclosed are pharmaceutical compositions comprising said compounds and methods of making said compounds. The compounds of the disclosure are useful in treating or...
|
WO/2023/179600A1 |
Disclosed in the present invention are novel substituted macroheterocyclic compounds, which can be used as inhibitors for targets such as ALK mutations, or ALK mutation related signaling pathways, for example NTRKs, ROS1, BRAF, c-MET, EG...
|
WO/2023/136213A1 |
The purpose of the present invention is to provide: a photochromic compound that has excellent temperature dependence, decoloration speed, and durability; a naphthol derivative that can be an intermediate of the photochromic compound; a ...
|
WO/2023/125825A1 |
Provided are compounds which exhibit activity in the inhibition of 3-chymotrypsin-like protease as well as pharmaceutical compositions comprising these compounds and methods of treatment of viral infections by administration of these com...
|
WO/2023/098752A1 |
Disclosed are a non-fluorinated quinolone compound and an application thereof, specifically relating to a compound represented by formula (II) and a pharmaceutically acceptable salt thereof.
|
WO/2023/088167A1 |
Provided are certain BCL-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
|
WO/2023/087027A1 |
Described herein are compounds that are ULK1/2 inhibitors and their use in the treatment of disorders such as cancers.
|
WO/2023/065606A1 |
Disclosed is a new deuterated cyano compound as represented by formula I, or a pharmaceutically acceptable salt, an isomer or a prodrug thereof. Further disclosed are a method for preparing the deuterated compound, and a composition and ...
|
WO/2023/059817A1 |
A hydrochloride salt of inupadenant, pharmaceutical compositions thereof, methods of making pharmaceutical compositions of a hydrochloride salt of inupadenant (e.g., crystalline hydrochloride salt of inupadenant) and methods of using the...
|
WO/2023/031958A1 |
The present invention is related to novel process for preparation of Trabectedin which involves less expensive reagents, solvents and the process conditions can be easily adopted for commercial scale.
|
WO/2023/031132A1 |
The invention relates to an improved method for producing mixtures containing 2-(2-hydroxyethyl)-piperidinyl carbamide acid secondary butyl ester from a raw product by means of a thermal treatment with short dwell times, to devices for s...
|
WO/2022/265993A1 |
This disclosure provides compounds of Formula (I), Formula (II), and pharmaceutically acceptable salts thereof, that inhibit phosphatidylinositol 4,5-bisphosphate 3-kinase (PI3K) isoform alpha (PI3Ka). These chemical entities are useful,...
|
WO/2022/253294A1 |
The present disclosure provides a pyridone compound having integrase inhibitory activity and a pharmaceutical use thereof. Specifically, the present disclosure provides a compound having a structure shown as formula I or a pharmaceutical...
|
WO/2022/250347A1 |
The present invention relates to an organic sulfur compound preparation method, and more specifically to an organic sulfur compound preparation method in which an organic sulfur compound is synthesized by reacting a specific compound wit...
|
WO/2022/195022A1 |
The present invention relates to new 5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3d]pyrimidin-4(3
H)-one derivatives as sigma ligands having a great affinity for sigma receptors, especially sigma-1 (σ1), as well as to the process for th...
|
WO/2022/095772A1 |
The present invention belongs to the technical field of new energy, and in particular relates to a lithium ion battery non-aqueous electrolyte and a lithium ion battery. The lithium ion battery non-aqueous electrolyte comprises a non-aqu...
|
WO/2022/092430A1 |
The present invention relates to a method for producing an organic sulfur compound, and more specifically relates to a method for producing an organic sulfur compound in which a specific compound is reacted with a metal hypohalite in the...
|
WO/2022/092429A1 |
The present invention relates to a method for producing an organic sulfur compound, and more specifically relates to a method for producing an organic sulfur compound in which a specific compound is reacted with a metal hypohalite in the...
|
WO/2022/092833A1 |
The present invention relates to a method for in-situ preparation of an organic sulfur compound, the method comprising: a solventless cyclization step in which dihalogen-based cyclization agent is fed to alkylene glycol, followed by stir...
|
WO/2022/048013A1 |
Disclosed is a method for preparing cyclic sulfate by direct oxidation of hydrogen peroxide, comprising: dropwise adding hydrogen peroxide into a mixture of cyclic sulfite, an organic solvent and a solid catalyst to carry out a catalytic...
|
WO/2021/250648A1 |
The invention relates to compounds of Formula (I'') wherein R, R1, R2, R3, p, q and q' are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient b...
|
WO/2021/241246A1 |
Provided are a radiation-sensitive resin composition capable of exhibiting adequate levels of sensitivity, LWR performance, and CDU performance, and a method for forming a pattern. This radiation-sensitive resin composition contains a so...
|
WO/2021/151922A1 |
The invention relates to benzimidazole derivatives which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing said compounds.
|
WO/2021/111124A1 |
The present invention relates to compounds of formula (I) that function as inhibitors of METTL3 (N6-adenosine-methyltransferase 70 kDa subunit) enzyme activity: X-Y-Z (I) wherein X, Y and Z are each as defined herein. The present inventi...
|
WO/2021/105706A1 |
A composition comprising an electron donor material and a first electron accepting material wherein the electron donor material is a polymer; the electron accepting material is a non- polymeric compound; and the electron donor material a...
|
WO/2021/024925A1 |
The present invention aims to provide: a chemically amplified positive photosensitive resin composition that contains an acid generator having excellent solvent solubility and can readily form a resist pattern having excellent mask linea...
|
WO/2020/234636A1 |
Present invention relates to the novel heterocyclic compounds of the general formula (I) their tautomeric forms, their stereoisomers and their pharmaceutically acceptable salts etc. The invention also relates to pharmaceutical compositio...
|
WO/2020/135872A1 |
Provided are a drug, a pharmaceutical composition, or a pharmaceutical kit for immunosuppression, for the treatment of conditions such as psoriasis, comprising a forskolin derivative or a salt thereof and optionally a prostaglandin compo...
|
WO/2020/106028A1 |
The present specification provides a compound represented by chemical formula 1 and an organic light-emitting device comprising same.
|
WO/2020/103864A1 |
Disclosed is compound of formula I and the pharmaceutically acceptable salts and solvates thereof, wherein R, R1a, R1b, R1h, L1, L2, L3, Ⓐ, Ⓑ, Ⓒ are as defined as set forth in the specification. Disclosed is compound of formula I f...
|
WO/2020/091522A1 |
The present specification provides a compound of chemical formula 1 and an organic light emitting device comprising same.
|
WO/2020/053263A1 |
The present invention relates to thiocarbamate derivatives of Formula (I) which are useful as A2A adenosine receptor (A2AR) inhibitors (I). Especially, the present invention relates to a pharmaceutical composition comprising an A2A inhib...
|
WO/2019/155363A1 |
The present invention relates to benzo-imidazoindolizine derivatives, organic electroluminescence devices comprising said derivative, and the use of said derivative in organic electroluminescence devices.
|
WO/2019/144805A1 |
Provided are a substituted phenylethylamine compound as a μ opioid receptor agonist, a pharmaceutical composition comprising same, a preparation method therefor and the use of same for preventing and/or treating diseases associated with...
|
WO/2019/118973A1 |
The present invention relates to novel compounds of formula (I) or formula (Ia), pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof, and pharmaceutical compositions of these compounds which are useful for pre...
|
WO/2019/013249A1 |
A chromene compound showing a reduced matrix dependency and having at least one indenonaphthopyran structure which carries a group forming a spiro ring together with the carbon atom at the 13-position, wherein the indenonaphthopyran stru...
|
WO/2018/215318A1 |
The invention relates to heteroaromatic compounds, particularly for use in electronic devices. The invention further relates to a method for producing the compounds according to the invention and to electronic devices containing same.
|
WO/2018/178338A1 |
The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof. The invention further relates to the use of the compounds of Formula (I) as A2A inhibitors. The invention also relates to...
|
WO/2018/019254A1 |
The present invention discloses a diphenyl ketone-based compound and an application thereof in an organo-electroluminescent device. The compound has the properties of limited intermolecular crystallization, limited clustering, and excell...
|
WO/2017/219917A1 |
Provided in the present invention is a new method for preparing a trabectedin, using safracin B as the starting material and through a series of reactions synthesizing trabectedin. The method easily obtains raw materials, has fewer synth...
|
WO/2017/213379A1 |
The present specification relates to an organic transistor comprising an organic semiconductor layer containing a compound and a gas sensor employing the same.
|
WO/2017/151947A1 |
The present disclosure relates to 4-azapodophylotoxins compounds, pharmaceutical compositions comprising such compounds, kits, and methods for using such compounds or pharmaceutical compositions.
|
WO/2017/147161A1 |
Described herein are compounds, compositions, and methods of their use for the treatment of dermatological disorders or conditions.
|
WO/2017/134984A1 |
The invention provides a method for obtaining 2-methylspiro (1,3-oxathiolane-5,3') quinuclidine sulfate at a high isomer ratio (cis/trans) from 3-hydroxy-3-mercaptomethylquinuclidine without requiring fractionation of isomers or an isome...
|
WO/2017/121444A1 |
Compounds of the formula (I) in which X1, X2, X3, X4, R1, R2, R3, Q and Y have the meanings indicated in Claim 1, are inhibitors of c-Kit kinase, and can be employed for the treatment of cancer.
|
WO/2017/020429A1 |
A nonaqueous electrolyte for a high-voltage lithium-ion battery and a lithium-ion battery. The electrolyte comprises a nonaqueous organic solvent, a lithium salt, and a double-nitrite compound selected from the structural formula 1, n be...
|
WO/2016/141563A1 |
The present invention aims to provide a novel alicyclic epoxide that is useful as a raw material of 2-hydroxyl-4-oxa-5-thia tricycle[4.2.1.03,7] nonane derivative. The alicyclic epoxide of the present invention is a compound represented ...
|
WO/2016/131521A1 |
The present invention relates to spirobifluorene derivatives of formula (I), the use thereof in electronic devices, and methods for producing said derivatives.
|
WO/2016/127924A1 |
The present invention relates to novel tricyclic compounds which can bind to FXR and act as modulators of the FXR, or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acce...
|